英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Orionis查看　Orionis　在百度字典中的解释百度英翻中〔查看〕
Orionis查看　Orionis　在Google字典中的解释Google英翻中〔查看〕
Orionis查看　Orionis　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Homepage - Orionis Biosciences
    Orionis is a clinical-stage life sciences company pioneering the development of novel precision medicines Our drug modalities – including molecular glues, cytokines, and cell engagers – harness the body’s natural defense mechanisms to fight cancer more effectively
  • About Us - Orionis Biosciences
    Orionis Bioscience, operated by a world-class team and backed by long-term transatlantic investors, integrates multidisciplinary expertise—disease biology, immunology, chemistry, protein engineering, computational science, and specialized AI—to develop precision therapies across molecular glues, conditional cytokines, and cell engagers
  • Orionis Biosciences Announces Strategic Partnership with Genentech to . . .
    Orionis announced its first collaboration with Genentech, to discover novel small-molecule medicines for challenging targets in major disease areas, including oncology and neurodegeneration, in September 2023
  • Platforms - Orionis Biosciences
    Orionis has developed three transformative technology platforms While technologically distinct, addressing small and large molecules, they all harness proximity and cooperativity mechanisms in drug mode of action
  • Orionis Biosciences Announces Collaboration with Genentech to Discover . . .
    Orionis will leverage its Allo-Glue™ platform for discovery of small molecule monovalent glues September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated drug discovery and chemical biology platform, announced today a multi-year Learn more
  • News - Orionis Biosciences
    Boston, MA Ghent, Belgium – Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today presented preclinical data supporting its A-Kine™ platform for rational design of cis-acting immuno-cytokines at the 14th Annual PEGS Europe Protein Antibody Engineering
  • Orionis Biosciences Debuts with Major Pharmaceutical Collaboration
    Orionis Biosciences is today debuting with the announcement of a major drug discovery collaboration with Novartis Orionis has developed innovative technologies in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities to tackle the industry’s most intractable disease targets
  • Orionis Biosciences Announces First Patient Dosed in Phase 1 Clinical . . .
    Orionis is evaluating ORB-011 in a Phase 1 open-label dose-escalation study (NCT05947474) for patients with recurrent or refractory solid tumors amenable to medically safe serial biopsies, including, but not limited to, colorectal cancer, HR+ or triple-negative breast cancer, non-small cell lung cancer, pancreatic cancer, head and neck squamous
  • Orionis Biosciences Secures $55 Million Financing to Support . . .
    Orionis is rapidly advancing a deep pipeline of biologics for the treatment of cancer based on its A-Kine™ platform, which engineers target-selective, conditionally active cytokines designed to trigger anti-tumor immune responses even in “cold” tumors that lack prevalent immune involvement and are refractory to checkpoint inhibitor therapies





中文字典-英文字典  2005-2009